Quick orientationEvidence update: 6 October 2026
What is GHRP-2?
GHRP-2 is a growth-hormone-releasing peptide that activates the ghrelin or growth-hormone-secretagogue receptor, GHS-R1a.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Small human physiological studies measured GH responses.
What the mechanism suggests
Ghrelin/growth-hormone secretagogue receptor (GHSR) agonist that stimulates GH release and can affect appetite and other pituitary hormones.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Ghrelin/growth-hormone secretagogue receptor (GHSR) agonist that stimulates GH release and can affect appetite and other pituitary hormones.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
GHRP-2 appetite experiment in healthy men — 2005
Crossover infusion study · 7 lean healthy menDuring GHRP-2 infusion, every participant ate more at an ad-libitum buffet; mean food intake was about 35.9% higher than during saline.
GHRP-2 clearly engages ghrelin-receptor biology in humans; appetite stimulation is not merely forum folklore.
What it doesn't prove: Very small acute physiology study, not a long-term body-composition trial.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| Healthy men | 100 mcg SC once daily | 5 days | Fixed | Human study; response attenuation observed |
| Older adults | 1 mcg/kg/hour continuous SC infusion | 30 days | Continuous fixed infusion | Human chronic study |
| Diagnostic/acute research | 100 mcg IV single dose | Single test | None | Human diagnostic/physiology research |
| Critical illness | 1 mcg/kg/hour infusion | 5 days | Continuous | Human clinical physiology study |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Lower-start pattern | 100 mcg SC per dose | 1–3× daily | Usually fixed | Community |
| Common pattern | 100–200 mcg SC per dose | 2–3× daily | Some start at 100 then increase | Community |
| Upper recurring pattern | 300 mcg SC per dose | 1–2× daily; some sources say up to 3× | Usually not a formal ladder | Community |
| Cycling convention | 100–300 mcg per dose, often 5 days on / 2 off | ~8 weeks; 4–8 weeks off reported | No loading phase | Community |
The community's repeated SC boluses are not the same regimen as the strongest chronic human study, which used continuous weight-based infusion. A 5-day human SC study also found attenuation of the GH response.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Hormone changes do not automatically establish recovery, muscle or anti-ageing benefits.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
GHRP-2 clearly engages ghrelin-receptor biology in humans; appetite stimulation is not merely forum folklore.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.